PL2219675T3 - Formulacja dla białek fuzyjnych TACI-immunoglobulina - Google Patents
Formulacja dla białek fuzyjnych TACI-immunoglobulinaInfo
- Publication number
- PL2219675T3 PL2219675T3 PL08850454T PL08850454T PL2219675T3 PL 2219675 T3 PL2219675 T3 PL 2219675T3 PL 08850454 T PL08850454 T PL 08850454T PL 08850454 T PL08850454 T PL 08850454T PL 2219675 T3 PL2219675 T3 PL 2219675T3
- Authority
- PL
- Poland
- Prior art keywords
- taci
- formulations
- fusion proteins
- immunoglobulin fusion
- immunoglobulin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120490 | 2007-11-12 | ||
| EP07120489 | 2007-11-12 | ||
| US302807P | 2007-11-14 | 2007-11-14 | |
| US298807P | 2007-11-14 | 2007-11-14 | |
| US7203808P | 2008-03-27 | 2008-03-27 | |
| EP08005923 | 2008-03-27 | ||
| EP08850454.3A EP2219675B1 (en) | 2007-11-12 | 2008-11-12 | Formulations for taci-immunoglobulin fusion proteins |
| PCT/EP2008/065395 WO2009062960A1 (en) | 2007-11-12 | 2008-11-12 | Formulations for taci-immunoglobulin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2219675T3 true PL2219675T3 (pl) | 2014-04-30 |
Family
ID=40347890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08850454T PL2219675T3 (pl) | 2007-11-12 | 2008-11-12 | Formulacja dla białek fuzyjnych TACI-immunoglobulina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8637021B2 (pl) |
| EP (1) | EP2219675B1 (pl) |
| JP (1) | JP5469077B2 (pl) |
| CN (2) | CN101854951A (pl) |
| AU (1) | AU2008322930B2 (pl) |
| CA (1) | CA2705357C (pl) |
| DK (1) | DK2219675T3 (pl) |
| ES (1) | ES2436779T3 (pl) |
| IL (1) | IL205716A (pl) |
| PL (1) | PL2219675T3 (pl) |
| PT (1) | PT2219675E (pl) |
| WO (1) | WO2009062960A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| WO2007019573A2 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| CN101678106B (zh) | 2007-03-27 | 2013-06-05 | 津莫吉尼蒂克斯公司 | 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合 |
| HUE030134T2 (en) | 2007-10-16 | 2017-04-28 | Zymogenetics Inc | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases |
| US8741591B2 (en) | 2009-10-09 | 2014-06-03 | The Research Foundation For The State University Of New York | pH-insensitive glucose indicator protein |
| CN102085367B (zh) * | 2011-01-19 | 2012-08-22 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ctla-4変異型免疫調節タンパク質およびそれらの使用 |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| AU2020401160B2 (en) * | 2019-12-10 | 2024-11-14 | Remegen Co., Ltd. | Pharmaceutical TACI-Fc fusion protein formulation |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| PH12022553243A1 (en) * | 2020-06-02 | 2024-02-12 | Ares Trading Sa | Methods related to the treatment of iga nephropathy |
| US20240301031A1 (en) * | 2021-03-31 | 2024-09-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Truncated taci polypeptide and fusion protein and use thereof |
| CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
| BR112023018745A2 (pt) * | 2021-08-10 | 2024-03-12 | Remegen Co Ltd | Método para tratar nefropatia por iga com proteína de fusão de taci-fc |
| CN117916273A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
| KR20240014066A (ko) * | 2021-09-30 | 2024-01-31 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법 |
| CN121152636A (zh) * | 2023-07-06 | 2025-12-16 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法 |
| WO2026008004A1 (zh) * | 2024-07-04 | 2026-01-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2635352C (en) * | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| WO1999032135A1 (en) * | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| WO2001060397A1 (en) * | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| WO2001087977A2 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| US20080267965A1 (en) * | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
| CN103520735B (zh) * | 2004-12-22 | 2015-11-25 | Ambrx公司 | 包含非天然编码的氨基酸的人生长激素配方 |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| AU2006318583A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
-
2008
- 2008-11-12 DK DK08850454.3T patent/DK2219675T3/da active
- 2008-11-12 CA CA2705357A patent/CA2705357C/en active Active
- 2008-11-12 PL PL08850454T patent/PL2219675T3/pl unknown
- 2008-11-12 ES ES08850454.3T patent/ES2436779T3/es active Active
- 2008-11-12 EP EP08850454.3A patent/EP2219675B1/en active Active
- 2008-11-12 AU AU2008322930A patent/AU2008322930B2/en active Active
- 2008-11-12 PT PT88504543T patent/PT2219675E/pt unknown
- 2008-11-12 CN CN200880115935A patent/CN101854951A/zh active Pending
- 2008-11-12 US US12/740,845 patent/US8637021B2/en active Active
- 2008-11-12 WO PCT/EP2008/065395 patent/WO2009062960A1/en not_active Ceased
- 2008-11-12 JP JP2010532619A patent/JP5469077B2/ja active Active
- 2008-11-12 CN CN201510626737.9A patent/CN105168123B/zh active Active
-
2010
- 2010-05-12 IL IL205716A patent/IL205716A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PT2219675E (pt) | 2013-11-18 |
| CN105168123A (zh) | 2015-12-23 |
| EP2219675A1 (en) | 2010-08-25 |
| CN101854951A (zh) | 2010-10-06 |
| IL205716A (en) | 2014-09-30 |
| JP5469077B2 (ja) | 2014-04-09 |
| ES2436779T3 (es) | 2014-01-07 |
| US8637021B2 (en) | 2014-01-28 |
| IL205716A0 (en) | 2010-11-30 |
| AU2008322930B2 (en) | 2014-05-15 |
| CA2705357C (en) | 2018-10-23 |
| CN105168123B (zh) | 2019-03-08 |
| WO2009062960A1 (en) | 2009-05-22 |
| CA2705357A1 (en) | 2009-05-22 |
| EP2219675B1 (en) | 2013-10-23 |
| JP2011503038A (ja) | 2011-01-27 |
| AU2008322930A1 (en) | 2009-05-22 |
| US20100297122A1 (en) | 2010-11-25 |
| DK2219675T3 (da) | 2013-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL205716A0 (en) | Formulations for taci-immunoglobulin fusion proteins | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| EP1988922A4 (en) | PROTEIN FORMULATIONS | |
| IL202128A0 (en) | Immunoglobulin fusion proteins | |
| EP2225275A4 (en) | PROTEIN FORMULATION | |
| IL202648A0 (en) | Antibody formulations | |
| IL222924A0 (en) | Albumin fusion proteins | |
| IL202950A0 (en) | Antibody formulations | |
| IL197580A0 (en) | Albumin fusion proteins | |
| PL3118220T3 (pl) | Białko | |
| ZA200908649B (en) | Rage fusion proteins | |
| ZA200905636B (en) | Stable antibody formulations | |
| EP2173163A4 (en) | ANTIBODY FORMULATIONS | |
| LT2144924T (lt) | Sulieto baltymo vakcina | |
| IL202225A0 (en) | Growth hormone fusion proteins | |
| GB0611116D0 (en) | Proteins | |
| GB0719231D0 (en) | Protein | |
| GB0601976D0 (en) | Proteins | |
| GB0725201D0 (en) | Peptide fusion proteins | |
| GB0724360D0 (en) | Method for preparing protein conjugates | |
| EP2167635A4 (en) | ANTIBODY FORMULATIONS | |
| GB0724357D0 (en) | Method for preparing protein conjugates | |
| GB0700759D0 (en) | Novel fusion protein | |
| GB0720563D0 (en) | Protein |